CN104910217B - Reference compound for Fondaparinux sodium quality control - Google Patents
Reference compound for Fondaparinux sodium quality control Download PDFInfo
- Publication number
- CN104910217B CN104910217B CN201510345330.9A CN201510345330A CN104910217B CN 104910217 B CN104910217 B CN 104910217B CN 201510345330 A CN201510345330 A CN 201510345330A CN 104910217 B CN104910217 B CN 104910217B
- Authority
- CN
- China
- Prior art keywords
- reference compound
- fondaparinux sodium
- solution
- water
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical technology field of the present invention, is related to a kind of reference compound for Fondaparinux sodium quality control.The related reference compound of Fondaparinux sodium of the present invention, including reference compound A (Rrt0.45), reference compound B (Rrt0.54), reference compound C (Rrt0.77), reference compound D (Rrt0.93), reference compound E (Rrt1.20).
Description
Technical field
Pharmaceutical technology field of the present invention, is related to a kind of quality determining method for Fondaparinux sodium bulk pharmaceutical chemicals, and related
Five reference compounds.
Technical background
Fondaparinux sodium is that first antithrombase of French Sanofi Winthrop Industrie development and production relies on
Property Xa factor indirect inhibitor, by 50 multisteps it is fully synthetic have across significance of times anticoagulation medicine.
Fondaparinux sodium is a kind of five Carbohydrate drugs of heparin, the entitled Fondaparinux sodium of its English, Chinese chemistry
It is entitled：Methyl O- (2- deoxidation -6-O- sulfonic group -2- sulfoamido-α-D- glucopyranoses)-(1 → 4)-O- (β-D- pyrans
Glucuronic acid)-(1 → 4)-O- (2- deoxidation -3,6-O- disulfonic acid base -2- sulfoamido-α-D- glucopyranoses)-(1 →
4)-O- (2-O- sulfonic group-α-L- pyrans iduronic acid)-(1 → 4) -2- deoxidation -6-O- sulfonic group -2- sulfoamido-α-D-
Ten sodium salt of glucopyranoside, chemical structural formula are following (representing 5 monose from left to right respectively with DEFGH)：
Complicated, the synthetic route length of Fondaparinux sodium, is degrading and can produce some impurity in building-up process.At present
The country has no the document patent report for being related to the research of Fondaparinux sodium impurity, and external related report is also seldom, and simply sulphur is reached
Liver last of the ten Heavenly stems sodium impurity carries out HPLC positioning and structure prediction, and specially Fondaparinux sodium impurity is not separated and structure mirror
It is fixed.
Applicant thinks that carrying out research to Fondaparinux sodium impurity is highly desirable, and not only facilitates raising Fondaparinux sodium
Purity, and the quality standard of product can be further improved.
Since the polarity between Fondaparinux sodium and impurity is close, the separating difficulty of impurity is very big；And impurity
Content is seldom, it is difficult to carry out preparative separation by common method.Further, since the molecular weight of impurity is big, it is complicated, it is necessary to
A certain amount of impurity could meet that the analyses such as HPLC, MS and NMR detect, therefore, it is difficult to which preparative separation obtains enough impurity pair
It carries out Structural Identification.
The content of the invention
It is an object of the invention to provide the related reference compound of Fondaparinux sodium.
Reference compound of the present invention is also referred to as impurity.
The related reference compound of Fondaparinux sodium of the present invention, including reference compound A (Rrt0.45), reference
Compound B (Rrt0.54), reference compound C (Rrt0.77), reference compound D (Rrt0.93), reference compound E
(Rrt1.20)。
These reference compounds can be the offer base of the quality research of Fondaparinux sodium, quality control and safety research
Plinth.Further, it is also possible to further carry out the research of pharmacology and toxicology to it, the effect in terms of its potential pharmacology is found.
The related reference compound of 5 Fondaparinux sodiums of the present invention, respectively relative retention time Rrt0.45,
Rrt0.54, Rrt0.77, Rrt0.93 and Rrt1.20.
Wherein Rrt0.45, Rrt0.54, Rrt0.77 are degradation impurity, are obtained by chemical synthesis；Rrt0.93 and
Rrt1.20 is synthesis impurity, isolated from Fondaparinux sodium crude product.
In these impurity, Rrt0.93 is known compound, and Rrt0.54 and Rrt0.77 are disclosed by usp37, Rrt0.45
It is unknown impuritie with Rrt1.20, belongs to new compound, domestic and foreign literature patent does not report it at present.
Wherein, degradation impurity：Reference compound A (Rrt0.45), reference compound B (Rrt0.54), reference compound C
(Rrt0.77)
Reference compound A (Rrt0.45), Chinese chemical name are known as：Methyl O-2- amino-(2- deoxidation -6-O- sulfonic groups -
2- sulfoamido-α-D- glucopyranoses)-(1 → 4)-O-6- carboxyls-(β-D- glucopyras alditol)-acid amides-(1 → 4)-O-
(2- deoxidation -3,6-O- disulfonic acid base -2- sulfoamido-α-D- glucopyranoses)-(1 → 4)-O- (2-O- sulfonic group-α-L- pyrroles
Mutter iduronic acid)-six sodium salt of (1 → 4) -2- deoxidation -6-O- sulfonic group -2- sulfoamido-α-D- glucopyranosides, chemistry
Structural formula is following (representing 5 monose from left to right respectively with D, E, F, G, H)：
Reference compound B (Rrt0.54), Chinese chemical name are known as：Methyl O- (4- deoxidation -2- sulfonyl-α-L- pyrans -
Hex- 4- glycals acid)-(1 → 4) -2- deoxidation -6-O- sulfonic group -2- sulfoamido-α-D- glucopyranoside tetrasodium salts, chemistry
Structural formula is following (representing 2 monose from left to right respectively with G, H)：
Reference compound C (Rrt0.77), Chinese chemical name are known as：Methyl O- (2- deoxidation -6-O- sulfonic group -2- sulfonamide
Base-α-D- glucopyranoses)-(1 → 4)-O- (beta d glucopyranosiduronic acid)-(1 → 4)-O- (bis- sulphurs of 2- deoxidations -3,6-O-
Acidic group -2- amino-α-D- glucopyranoses)-(1 → 4)-O- (2-O- sulfonic group-α-L- pyrans iduronic acid)-(1 → 4) -
Nine sodium salt of 2- deoxidation -6-O- sulfonic group -2- sulfoamido-α-D- glucopyranosides, chemical structural formula it is following (with D, E, F, G,
H represents 5 monose from left to right respectively)：
Synthesize impurity：Reference compound D (Rrt0.93), reference compound E (Rrt1.20)
Reference compound D (Rrt0.93), Chinese chemical name are known as：Methyl O- (2- deoxidation -6-O- sulfonic group -2- formamides
Base-α-D- glucopyranoses)-(1 → 4)-O- (beta d glucopyranosiduronic acid)-(1 → 4)-O- (bis- sulphurs of 2- deoxidations -3,6-O-
Acidic group -2- sulfoamido-α-D- glucopyranoses)-(1 → 4)-O- (2-O- sulfonic group-α-L- pyrans iduronic acid)-(1 →
4) nine sodium salt of -2- deoxidations -6-O- sulfonic groups -2- sulfoamido-α-D- glucopyranosides, chemical structural formula it is following (with D, E,
F, G, H represent 5 monose from left to right respectively)：
Reference compound E (Rrt1.20), Chinese chemical name are known as：Methyl O- (2- deoxidation -6-O- sulfonic group -2- sulfonamide
Base-α-D- glucopyranoses)-(1 → 4)-O- (β-D-3,6- glucopyranosiduronic acids ester)-(1 → 4)-O- (2- deoxidations -3,6-
O- disulfonic acid base -2- sulfoamido-α-D- glucopyranoses)-(1 → 4)-O- (2-O- sulfonic group-α-L- pyrans idose aldehyde
Acid)-nine sodium salt of (1 → 4) -2- deoxidation -6-O- sulfonic group -2- sulfoamido-α-D- glucopyranosides, chemical structural formula is as follows
(representing 5 monose from left to right respectively with D, E, F, G, H)：
It is another object of the present invention to provide preparation method of the Fondaparinux sodium in relation to reference compound.
The access approaches of the reference compound of Fondaparinux sodium of the present invention, by synthesis, and from Fondaparinux sodium
It is isolated in crude product.
Specifically, the preparation method of reference compound A (Rrt0.45) of the present invention, comprises the following steps：
Fondaparinux sodium sterling 1.5g is weighed in 500ml round-bottomed flasks, then adds the HCl of 300ml 1mol/L thereto
Aqueous solution, 40 DEG C of oil bath, acid degradation reference compound A (Rrt0.45) can be produced after stirring 18h.Add the NaOH tune of 1mol/L
PH is saved to alkalescence, the chromatographic column desalination of sephadex G -25 is concentrated under reduced pressure into dry, obtains reference compound A crude products.
Reference compound A crude products are weighed, are dissolved with purified water, using high performance preparative liquid chromatography instrument, select strong base cloudy
Ion-exchange chromatography DIONEX CarboPac TMPA1 (250 × 9mm), carry out loading separation in multiple times on a small quantity, and flow velocity is
5.0ml/min, ultraviolet wavelength 210nm, mobile phase A, B carry out gradient elution (mobile phase A：117g/L sodium-chloride water solutions, stream
Dynamic phase B：Water for injection), it is as shown in the table for gradient：
The efflux of 8.0min-11.3min is gathered, the chromatographic column desalination of sephadex G -25, obtains white after being concentrated under reduced pressure
Color solid reference compound A (Rrt0.45).
The preparation method of reference compound E (Rrt1.20) of the present invention, comprises the following steps：
In liquid phase preparative separation Fondaparinux sodium, its efflux is divided into three components：" preceding miscellaneous ", " main peak " and " after
It is miscellaneous ", reference compound E is present in " rear miscellaneous " component, through the chromatographic column desalination of sephadex G -25, is concentrated under reduced pressure into dry, obtains
Reference compound E crude products.
Wherein " main peak " is the ultraviolet absorption peak of Fondaparinux sodium in liquid phase, and " preceding miscellaneous " is the purple of " main peak " before in 5min
Outer absworption peak, " rear miscellaneous " are the ultraviolet absorption peak of " main peak " afterwards in 3min.
Reference compound E (Rrt1.20) crude product is weighed, using high performance preparative liquid chromatography instrument, selects strong base anion
Exchange chromatography column DIONEX CarboPac TMPA1 (250 × 9mm), carry out loading separation, flow velocity 5.0ml/ in multiple times on a small quantity
Min, ultraviolet wavelength 210nm, mobile phase A, B carry out gradient elution (mobile phase A：117g/L sodium-chloride water solutions, Mobile phase B：
Water for injection), it is as shown in the table for gradient：
The efflux of 14.6min-16.6min is gathered, the chromatographic column desalination of sephadex G -25, obtains white after being concentrated under reduced pressure
Color solid reference compound E (Rrt1.20).
Related reference compound it is another object of the present invention to provide Fondaparinux sodium is in detection Fondaparinux sodium
Application in quality.
Detection method of the present invention, using high effective liquid chromatography for measuring,
Specifically, to the polymeric anion exchange column (pre-column that quaternary ammonium anion shell resin is filler：Dionex
CarboPacTMPA Isosorbide-5-Nitraes × 50mm；Chromatographic column Dionex CarboPacTMPA Isosorbide-5-Nitraes × 250mm).Mobile phase：It is sub- with diformazan
Sulfone-water is mobile phase A (about 10 μ L dimethyl sulfoxides, 0.22 μm of membrane filtration are added in 1000ml ultra-pure waters), with 116.9g/L chlorine
Change sodium solution is Mobile phase B, and flow velocity 1.0ml/min, Detection wavelength 210nm, column temperature is 35 DEG C, and according to the form below carries out gradient and washes
It is de-.
Fondaparinux sodium reference compound according to the present invention, these reference compounds can be used as analysis sulphur to reach the liver last of the ten Heavenly stems
Reference substance during sodium impurity, provides basis, so as to improve for the quality research, quality control and safety research of Fondaparinux sodium
The quality standard of Fondaparinux sodium, important directive significance is provided for the clinical application of Fondaparinux sodium.
In addition, we further will carry out these unknown impurities the research of pharmacology and toxicology, it is potential to find its
Effect in terms of pharmacology.From a long-term perspective, these unknown impurities also have the researching value of higher.
Brief description of the drawings
Fig. 1：Chromatography testing result (auto zoom chromatogram)
Sample ID sulphur reaches+5 impurity；Gather the date 201,5/5,/19 16:44:28CST；Sampling volume 100.00；Processing
Passage illustrates W2489 ChA 210nm
Embodiment
By specific examples below, the present invention is further illustrated, but not as the limitation of the present invention.
1 reference compound A (Rrt0.45) of embodiment：
Fondaparinux sodium sterling 1.5g accurately is weighed in 500ml round-bottomed flasks, then adds 300ml 1mol/L thereto
HCl/water solution, 40 DEG C of oil bath, stir 18h after can produce acid degradation reference compound A (Rrt0.45).Add 1mol/L's
NaOH adjusts PH to alkalescence, the chromatographic column desalination of sephadex G -25, is concentrated under reduced pressure into dry, obtains reference compound A crude products.
Reference compound A (Rrt0.45) crude product is weighed, is dissolved with purified water, using high performance preparative liquid chromatography instrument, selection
Strong base anion exchange chromatography column DIONEX CarboPac TMPA1 (250 × 9mm), carry out loading separation in multiple times on a small quantity,
Flow velocity is 5.0ml/min, ultraviolet wavelength 210nm, and mobile phase A, B carry out gradient elution (mobile phase A：117g/L sodium chloride water
Solution, Mobile phase B：Water for injection), it is as shown in the table for gradient：
The efflux of 8.0min-11.3min is gathered, the chromatographic column desalination of sephadex G -25, obtains white after being concentrated under reduced pressure
Color solid reference compound A (Rrt045).
Reference compound A (Rrt0.45) hydrogen is composed and carbon modal data
Reference compound A (Rrt0.45) high resolution mass spectrum data
From the point of view of hydrogen spectrum is composed with carbon, compared with Fondaparinux sodium, the chemical shift of F rings becomes reference compound A (RRT0.45)
Change maximum, so inferring that 2 sulfonyls fall on F rings.With reference to mass spectrum, it should be to have fallen two sulfonyls.It is concluded that it is D rings
Upper 2 sulfonyls fall.Reason is：Reference compound A (RRT0.45) is obtained by acid degradation, so the sulphonyl on amino
Base is to be easiest to be struck off.From spatial configuration, if if the upper sulfonyl of 2, H rings falls, the chemical shift to H rings
Influencing can be bigger, so it is that 2 sulfonyls fall on D rings to infer.In addition the change of hydrogen spectrum is little on G rings, but carbon spectrum chemical shift
Change greatly, deduction is due to that G rings are idose, its spatial configuration can exchange between boat form and chair form, the change of steric configuration
Change the change for causing carbon chemical shifts on G rings.Detected by high resolution mass spectrum (ESI anions), infer the essence of the compound
Really molecular weight is：1522.8933 molecular formula C31H45N3Na8O43S6, structural formula is as follows：
2 reference compound B (Rrt0.54) of embodiment：
Fondaparinux sodium sterling 1.5g, NaCl 2.5g accurately is weighed, in 500ml soda-lime glass bottles, then is added thereto
300ml purified waters, are sealed with aluminium-plastic combined cover, and high temperature reference compound B can be produced after 130 DEG C of heating 2.5h in baking oven
(Rrt0.54).Through the chromatographic column desalination of sephadex G -25, it is concentrated under reduced pressure into dry, obtains reference compound B crude products.
Reference compound B (Rrt0.54) crude product is weighed, is dissolved with purified water, using high performance preparative liquid chromatography instrument, is prepared
Condition and separating step as shown in Example 1, that is, obtain white solid reference compound B (Rrt0.54).
Reference compound B (Rrt0.54) hydrogen is composed and carbon modal data
Reference compound B (Rrt0.54) high resolution mass spectrum data
The hydrogen of methoxyl group also exists in hydrogen spectrum, 5.47,5.00 two anomeric carbons only occurs, and deduction is between F sugar and G sugar
Key fracture.Occurs obvious alkene hydrogen at chemical shift 5.94, G 5 hydrogen of sugar disappear, and may infer that G changes 4,5 shapes
Into double bond.Sugared 4 carbon of G and 5 carbon substantially shift to low field in carbon spectrum, in unsaturated bond position appearance, can also confirm be
4,5 formation double bonds.Detected by high resolution mass spectrum (ESI anions), the accurate molecular weight of the compound is：678.9148 point
Minor is C13H17NNa4O19S3, structural formula is as follows：
3 reference compound C (Rrt0.77) of embodiment：
Fondaparinux sodium sterling 1.0g accurately is weighed in 500ml round-bottomed flasks, then adds 200ml 1mol/L thereto
HCl/water solution, acid degradation reference compound C (Rrt0.77) can be produced after (20 DEG C) of room temperature stirring 65h.Add 1mol/L's
NaOH adjusts PH to alkalescence, the chromatographic column desalination of sephadex G -25, is concentrated under reduced pressure into dry, obtains reference compound C crude products.
Reference compound C (Rrt0.77) crude product is weighed, is dissolved with purified water, using high performance preparative liquid chromatography instrument, is prepared
Condition and separating step as shown in Example 1, that is, obtain white solid reference compound C (Rrt0.77).
Reference compound C (Rrt0.77) hydrogen is composed and carbon modal data
Reference compound C (Rrt0.77) high resolution mass spectrum data
It can be seen from hydrogen spectrum compared with Fondaparinux sodium, the only chemical shift of F ring hydrogens becomes there occurs obvious
Change, other positions change unobvious.Find out from carbon spectrum, very greatly, other rings are also unobvious for the chemical shift change of carbon on F rings.
Infer molecular formula with reference to mass spectrum, it can be determined that be that sulfonyl on F rings on 2 falls.From spatial configuration, sulfonyl
After having fallen, have a great influence to the electronic environment that F is changed so that the carbon chemical shifts of F rings are obviously changed.It is logical
High resolution mass spectrum (ESI cations, anion) detection is crossed, the accurate molecular weight of the compound is：1624.8320, molecular formula is
C31H44N3Na9O46S7, structural formula is as follows：
4 reference compound D (Rrt0.93) of embodiment：
In liquid phase preparative separation Fondaparinux sodium, three components are divided into：" preceding miscellaneous ", " main peak " and " rear miscellaneous ", work
Skill reference compound D is present in " preceding miscellaneous " component.Through the chromatographic column desalination of sephadex G -25, it is concentrated under reduced pressure into dry, must joins
Than compound D crude products.
Reference compound D (Rrt0.93) crude product is weighed, is dissolved with purified water, using high performance preparative liquid chromatography instrument, is prepared
Condition and separating step as shown in Example 1, that is, obtain white solid reference compound D (Rrt0.93).
Reference compound D (Rrt0.93) hydrogen is composed and carbon modal data
Reference compound D (Rrt0.93) high resolution mass spectrum detects data
In carbon spectrum, occur the peak of carbonyl carbon at 167.33, while 2 C of D sugar shift to High-Field 54.74 by 60.59, its
He does not change significantly the carbon of position, illustrates that there occurs obvious change for substituent only on D rings C2.In addition, in DEPT spectrums
Also there is the C on CHO, it was demonstrated that the non-quaternary carbon of carbonyl carbon.It can determine that 2 bit substituents become for formyl on D sugar in summary
Amino.Composed by hydrogen as can be seen that compared with Fondaparinux sodium, occur obvious CHO bases hydrogen at 8.17,
Since sugared 2 bit substituents of D are by NHSO3Na is changed into NHCHO, is influenced by electronic effect and three-dimensional effect, D sugar 2
Hydrogen chemical shifts shift to low field by 3.25 to 3.58, while sugared 1 hydrogen of D also has minor way, and High-Field 5.44 is shifted to by 5.59.This
Deduction with carbon spectrum is consistent.Detected by high resolution mass spectrum (ESI cations, anion), infer the accurate molecular of the compound
Measure and be：1652.8269 molecular formula C32H44N3Na9O47S7, structural formula is as follows：
5 reference compound E (Rrt1.20) of embodiment：
In liquid phase preparative separation Fondaparinux sodium, three components are divided into：" preceding miscellaneous ", " main peak " and " rear miscellaneous ", work
Skill reference compound E is present in " rear miscellaneous " component.Through the chromatographic column desalination of sephadex G -25, it is concentrated under reduced pressure into dry, must joins
Than compound E crude products.
Reference compound E (Rrt1.20) crude product is weighed, is dissolved with purified water, using high performance preparative liquid chromatography instrument, selection
Strong base anion exchange chromatography column DIONEX CarboPac TMPA1 (250 × 9mm), carry out loading separation in multiple times on a small quantity,
Flow velocity is 5.0ml/min, ultraviolet wavelength 210nm, and mobile phase A, B carry out gradient elution (mobile phase A：117g/L sodium chloride water
Solution, Mobile phase B：Water for injection), it is as shown in the table for gradient：
The efflux of 14.6min-16.6min is gathered, the chromatographic column desalination of sephadex G -25, obtains white after being concentrated under reduced pressure
Color solid reference compound E (Rrt1.20).
Reference compound E (Rrt1.20) hydrogen is composed and carbon modal data
Reference compound E (Rrt1.20) high resolution mass spectrum detects data
As can be seen that only having the hydrogen chemical shifts change of E sugar 3 is maximum to be moved by 3.82 compared with Fondaparinux sodium in hydrogen spectrum
3.62,4 hydrogen being shifted to by 3.41 to 4.48,2 hydrogen of low field and shifting to low field 4.04 by 3.82, the hydrogen of other positions is not obvious
Change.It can be seen that in being composed from carbon and only have E sugar 3 to change to shift to low field there occurs obvious compared with Fondaparinux sodium, other
Change in location very little.It can therefore be concluded that the substituent of E sugar 3 is changed.Sugared 3 hydroxyls of E are may infer that with reference to mass spectrum
By excessive sulfonation.Due to the sucting electronic effect of sulfonyl so that low field is shifted in the chemical shift of E 3 hydrogen of sugar, meanwhile, 2 and 4
Position hydrogen has also sent out different degrees of change.Detected by high resolution mass spectrum (ESI cations, anion), infer the compound
Accurate molecular weight be：1828.7095 molecular formula C31H42N3Na11O52S9, structural formula is as follows：
6 reference compound A (Rrt0.45) of embodiment, B (Rrt0.54), C (Rrt0.77), D (Rrt0.93) and E
(Rrt1.20) application as reference substance in Fondaparinux sodium medicine is detected.
Reference compound A (Rrt0.45), B (Rrt0.54), C (Rrt0.77), D (Rrt0.93) and E provided by the invention
(Rrt1.20) reference substance can be provided for the qualitative and quantitative analysis of Fondaparinux sodium, so as to improve the quality of Fondaparinux sodium
Standard, important directive significance is provided for the clinical application of Fondaparinux sodium.
The preparation of test solution：Precision weighs that Fondaparinux sodium is appropriate, and being dissolved in water and diluting is configured to contain in every 1ml
The solution of 5mg, is filtered, filtrate is as test solution with 0.45 μm of filter membrane；
Reference substance stock solution：Precision weighs reference compound A (Rrt0.45), B (Rrt0.54), C (Rrt0.77), D
(Rrt0.93) and E (Rrt1.20) reference substance is each appropriate, dissolve and diluted with water and is configured to the solution containing 25mg in every 1ml, work
For impurity reference substance stock solution；
Fondaparinux sodium reference substance solution：It is appropriate that precision weighs Fondaparinux sodium reference substance, is dissolved in water and dilutes preparation
The solution containing 25mg into every 1ml, as reference substance stock solution；
It is accurate respectively to measure impurity reference substance stock solution and each 1ml of reference substance stock solution, put in 5ml measuring bottles, use water
Scale is diluted to, is shaken up, as reference substance solution.
Chromatographic condition：
Measured according to high performance liquid chromatography (two V D of annex of China's coastal port).
Chromatographic condition is handed over system suitability to quaternary ammonium anion shell resin for the polymeric anion of filler
Change column (pre-column：Dionex CarboPacTMPA Isosorbide-5-Nitraes × 50mm；Chromatographic column Dionex CarboPacTMPA Isosorbide-5-Nitraes ×
250mm)；About 10 μ l dimethyl sulfoxide (DMSO)s, 0.22 μm of membrane filtration, as baseline produces positive (are added with water in l000ml ultra-pure waters
Drift, then increase the dosage of dimethyl sulfoxide (DMSO), dosage that is on the contrary then reducing dimethyl sulfoxide (DMSO), the actual amount of dimethyl sulfoxide is 10
~25 μ l are differed) mobile phase A is used as, with 11.69% sodium chloride solution (top grade pure sodium chloride 116.9g is taken, adds ultra-pure water to dissolve
And l000ml is diluted to, and 0.22 μm of membrane filtration) it is used as Mobile phase B；Flow velocity is 1.0ml/min, Detection wavelength 210nm, color
It is 25 DEG C to compose column temperature, and according to the form below is through row gradient elution：
| Time | Mobile phase A (%) | Mobile phase B (%) |
| 0 | 50 | 50 |
| 5 | 50 | 50 |
| 25 | 10 | 90 |
| 30 | 10 | 90 |
| 35 | 50 | 50 |
| 50 | 50 | 50 |
Fondaparinux sodium and reference compound A (Rrt0.45), B (Rrt0.54), C (Rrt0.77), D (Rrt0.93) and E
(Rrt1.20) separating degree between peak should be greater than 6.
Precision measures reference substance solution and each 100 μ l of test solution, injects liquid chromatograph, by given chromatographic condition into
Sample, records chromatogram.Fondaparinux sodium and A (Rrt0.45), B (Rrt0.54), C (Rrt0.77), D (Rrt0.93) and E
(Rrt1.20) separating degree between peak should be greater than 6.
Testing result is as shown in Figure 1.
Claims (3)
1. a kind of quality determining method of Fondaparinux sodium bulk pharmaceutical chemicals, includes the following steps：
The preparation of test solution：Precision weighs that Fondaparinux sodium is appropriate, and being dissolved in water and diluting is configured to contain 5mg in every 1ml
Solution, with 0.45 μm of membrane filtration, filtrate is as test solution；
Reference substance stock solution：It is each appropriate that precision weighs reference compound A, B, C, D and E reference substance, is dissolved and diluted with water and matched somebody with somebody
The solution containing 25mg in every 1ml is made, as impurity reference substance stock solution；
Fondaparinux sodium reference substance solution：It is appropriate that precision weighs Fondaparinux sodium reference substance, be dissolved in water and dilute be configured to it is every
Solution containing 25mg in 1ml, as reference substance stock solution；
It is accurate respectively to measure impurity reference substance stock solution and each 1ml of reference substance stock solution, put in 5ml measuring bottles, be diluted with water
To scale, shake up, as reference substance solution；
Chromatographic condition：
According to two annex of China's coastal port, V D high effective liquid chromatography for measuring,
Polymeric anion exchange column of the chromatographic condition with system suitability to quaternary ammonium anion shell resin for filler；
Using water as mobile phase A, Mobile phase B is used as using 11.69% sodium chloride solution；Flow velocity is 1.0ml/min, and Detection wavelength is
210nm, chromatographic column temperature are 25 DEG C, and according to the form below is through row gradient elution：
Precision measures reference substance solution and each 100 μ l of test solution, injects liquid chromatograph, by given chromatographic condition sample introduction,
Chromatogram is recorded, the separating degree between Fondaparinux sodium and A, B, C, D and E peak should be greater than 6；
Impurity A, B, C, D and E chemical constitution are as follows successively：
2. the quality determining method of Fondaparinux sodium bulk pharmaceutical chemicals as claimed in claim 1, it is characterised in that reference compound A's
Preparation method：
Fondaparinux sodium sterling 1.5g accurately is weighed in 500ml round-bottomed flasks, then adds the HCl of 300ml 1mol/L thereto
Aqueous solution, 40 DEG C of oil bath, acid degradation reference compound A can be produced after stirring 18h, added NaOH and adjusted pH to alkalescence, glucan
Gel G-25 chromatographic column desalinations, are concentrated under reduced pressure into dry, obtain reference compound A crude products；
Reference compound A crude products are weighed, are dissolved with purified water, using high performance preparative liquid chromatography instrument, select strong base anion
Exchange chromatography column DIONEX CarboPac TMPA1, loading separation, flow velocity 5.0ml/min, ultraviolet wavelength 210nm, flowing
Phase A, B carries out gradient elution, mobile phase A：117g/L sodium-chloride water solutions, Mobile phase B：Water for injection, it is as shown in the table for gradient：
The efflux of piecewise acquisition reference compound A, the chromatographic column desalination of sephadex G -25, it is solid to obtain white after being concentrated under reduced pressure
Body reference compound A, structure are as follows
3. the quality determining method of Fondaparinux sodium bulk pharmaceutical chemicals as claimed in claim 1, it is characterised in that reference compound E's
Preparation method：
In liquid phase preparative separation Fondaparinux sodium, its efflux is divided into three components：" preceding miscellaneous ", " main peak " and " rear miscellaneous ",
Technique reference compound E is present in " rear miscellaneous " component, through the chromatographic column desalination of sephadex G -25, is concentrated under reduced pressure into dry, obtains
Reference compound E crude products,
Reference compound E crude products are weighed, using high performance preparative liquid chromatography instrument, select strong base anion exchange chromatography column
DIONEX CarboPac TMPA1, loading separation, flow velocity 5.0ml/min, ultraviolet wavelength 210nm, mobile phase A, B are carried out
Gradient elution, mobile phase A：117g/L sodium-chloride water solutions, Mobile phase B：Water for injection, it is as shown in the table for gradient：
Collection " after it is miscellaneous " efflux, the chromatographic column desalination of sephadex G -25, obtains white solid reference after being concentrated under reduced pressure
Compound E, structure are as follows：
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510345330.9A CN104910217B (en) | 2015-06-19 | 2015-06-19 | Reference compound for Fondaparinux sodium quality control |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510345330.9A CN104910217B (en) | 2015-06-19 | 2015-06-19 | Reference compound for Fondaparinux sodium quality control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104910217A CN104910217A (en) | 2015-09-16 |
| CN104910217B true CN104910217B (en) | 2018-04-17 |
Family
ID=54079706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510345330.9A Active CN104910217B (en) | 2015-06-19 | 2015-06-19 | Reference compound for Fondaparinux sodium quality control |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104910217B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107501359B (en) * | 2017-08-24 | 2020-07-31 | 深圳市海滨制药有限公司 | Fondaparinux sodium impurity compound and preparation method and application thereof |
| CN107595769A (en) * | 2017-10-23 | 2018-01-19 | 上海博悦生物科技有限公司 | A kind of preparation method of Fondaparinux sodium injecta composition |
| CN108896696A (en) * | 2018-04-18 | 2018-11-27 | 南京健友生化制药股份有限公司 | Dissociate in a kind of Fondaparinux sodium injection the detection method of sulfate radical |
| CN109734757B (en) * | 2019-03-11 | 2020-09-11 | 淮北师范大学 | Preparation method of related substance B of fondaparinux sodium injection |
| CN114948974A (en) * | 2021-02-25 | 2022-08-30 | 南开大学 | Application of heparin pentasaccharide compound in preparation of sepsis medicine |
| CN114957354B (en) * | 2021-02-25 | 2023-11-24 | 南开大学 | Heparin pentasaccharide structure compound |
| CN114591379A (en) * | 2021-12-30 | 2022-06-07 | 淮北师范大学 | Preparation method of fondaparinux sodium formylation impurity |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001029055A2 (en) * | 1999-10-22 | 2001-04-26 | Aventis Pharma S.A. | Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| CN1558911A (en) * | 2001-09-07 | 2004-12-29 | Synthetic heparin pentasaccharides | |
| US20050020536A1 (en) * | 2003-02-27 | 2005-01-27 | Jean-Francois Branellec | Highly pure fondaparinux sodium composition, process for preparing said composition and pharmaceutical compositions containing it as active principle |
| US20150031866A1 (en) * | 2013-07-25 | 2015-01-29 | Scinopharm Taiwan, Ltd. | Process for the production of fondaparinux sodium |
| CN105596291A (en) * | 2014-11-24 | 2016-05-25 | 辽宁海思科制药有限公司 | Fondaparinux sodium injection composition |
-
2015
- 2015-06-19 CN CN201510345330.9A patent/CN104910217B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001029055A2 (en) * | 1999-10-22 | 2001-04-26 | Aventis Pharma S.A. | Novel oligosaccharides, preparation method and pharmaceutical compositions containing same |
| CN1558911A (en) * | 2001-09-07 | 2004-12-29 | Synthetic heparin pentasaccharides | |
| US20050020536A1 (en) * | 2003-02-27 | 2005-01-27 | Jean-Francois Branellec | Highly pure fondaparinux sodium composition, process for preparing said composition and pharmaceutical compositions containing it as active principle |
| US20150031866A1 (en) * | 2013-07-25 | 2015-01-29 | Scinopharm Taiwan, Ltd. | Process for the production of fondaparinux sodium |
| CN105596291A (en) * | 2014-11-24 | 2016-05-25 | 辽宁海思科制药有限公司 | Fondaparinux sodium injection composition |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104910217A (en) | 2015-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104910217B (en) | Reference compound for Fondaparinux sodium quality control | |
| Hardy | [7] Monosaccharide analysis of glycoconjugates by high-performance anion-exchange chromatography with pulsed amperometric detection | |
| CN104597160B (en) | HPLC (High Performance Liquid Chromatography) method for simultaneously determining content of six organic acids in pinellia ternata | |
| Koizumi et al. | Separation of cyclic (1→ 2)-β-D-glucans (cyclosophoraoses) produced by Agrobacterium and Rhizobium, and determination of their degree of polymerization by high-performance liquid chromatography | |
| CN109030658B (en) | Method for detecting fructo-oligosaccharide and raffinose in infant milk powder | |
| CN110320290A (en) | HPLC detection method of the Mecobalamin injection in relation to substance | |
| Wei et al. | A rapid ion chromatography column-switching method for online sample pretreatment and determination of L-carnitine, choline and mineral ions in milk and powdered infant formula | |
| CN104730009B (en) | The detection method of polyoses content in a kind of Tea Flower | |
| CN108732288B (en) | Method for detecting content of tranexamic acid or related substances thereof | |
| CN107505409B (en) | A method of measuring isomer impurities ginsenoside RK1 in ginsenoside RZ1 raw materials or preparation | |
| CN109374779A (en) | A kind of rapid detection method of cane sugar content | |
| CN111122740B (en) | Method for separating and determining related substances of oxaliplatin based on C18 bonded phase chromatographic column | |
| CN107561178A (en) | A kind of method of the quality evaluation of main chemical compositions in aloe products | |
| KR101552591B1 (en) | Method for Analysis of Suger chain composition | |
| CN115078568A (en) | Ultra-high performance liquid chromatography method for determining content and purity of hydroxytyrosol | |
| CN110568119B (en) | Method for simultaneously detecting betaine hydrochloride and methyl chloroacetate quaternary ammonium salt | |
| CN114609295A (en) | High performance liquid chromatography analysis method for quinic acid content in tala enzymolysis waste liquid | |
| CN107941937B (en) | A kind of method for separating and analyzing of oat alkaloid D and dihydro avenine D | |
| CN112697945A (en) | Method for analyzing content of posaconazole enteric-coated tablets | |
| CN111044636A (en) | Analytical method of micafungin content | |
| CN108760961B (en) | Method for detecting purity of solid potassium fomesate by liquid chromatography | |
| Charoenraks et al. | Micro-solvent cluster extraction using aqueous mixed solvents of ionic liquid | |
| CN113075320B (en) | Detection method and consistency evaluation method for azithromycin particle impurities | |
| CN105301122A (en) | Method for determination of contents of oleanolic acid and ursolic acid in kiwi fruit oil through high performance liquid chromatography | |
| CN101865896A (en) | Method for detecting impurities in nedaplatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |